Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001380435 | SCV001578513 | pathogenic | Focal segmental glomerulosclerosis 5; Charcot-Marie-Tooth disease dominant intermediate E | 2023-08-02 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt INF2 protein function. ClinVar contains an entry for this variant (Variation ID: 1053). This missense change has been observed in individual(s) with clinical features of focal segmental glomerulosclerosis (PMID: 20023659, 30126379, 30406062). It has also been observed to segregate with disease in related individuals. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces arginine, which is basic and polar, with histidine, which is basic and polar, at codon 214 of the INF2 protein (p.Arg214His). |
Genome Diagnostics Laboratory, |
RCV002293971 | SCV002587548 | likely pathogenic | Kidney disorder | 2016-12-12 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV001380435 | SCV002811492 | pathogenic | Focal segmental glomerulosclerosis 5; Charcot-Marie-Tooth disease dominant intermediate E | 2021-12-25 | criteria provided, single submitter | clinical testing | |
Eurofins- |
RCV000001108 | SCV003935065 | likely pathogenic | Focal segmental glomerulosclerosis 5 | 2022-11-03 | criteria provided, single submitter | clinical testing | |
OMIM | RCV000001108 | SCV000021258 | pathogenic | Focal segmental glomerulosclerosis 5 | 2010-01-01 | no assertion criteria provided | literature only |